JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
144.24
+1.18 (+0.82%)
At close: 4:00PM EDT

144.79 +0.51 (0.35%)
Pre-Market: 8:00AM EDT

Stock chart is not supported by your current browser
Previous Close143.06
Open143.27
Bid144.35 x 1200
Ask144.79 x 1000
Day's Range143.19 - 144.98
52 Week Range120.11 - 148.99
Volume7,509,067
Avg. Volume6,741,225
Market Cap382.966B
Beta (3Y Monthly)0.73
PE Ratio (TTM)26.73
EPS (TTM)5.40
Earnings DateJul 16, 2019
Forward Dividend & Yield3.80 (2.63%)
Ex-Dividend Date2019-05-24
1y Target Est149.17
Trade prices are not sourced from all markets
  • Here Are Johnson & Johnson’s Key Growth Drivers in Fiscal 2019
    Market Realist43 minutes ago

    Here Are Johnson & Johnson’s Key Growth Drivers in Fiscal 2019

    Johnson & Johnson’s (JNJ) Pharmaceutical segment is the company’s key revenue driver and accounted for 51.17% of the company’s total revenues in the first quarter. Darzalex, Stelara, Tremfya, and Imbruvica reported double-digit YoY revenue growth in the first quarter.

  • Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
    Zacks14 hours ago

    Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $144.24, moving +0.82% from the previous trading session.

  • Axsome Initiates Phase III Study on Depression Candidate
    Zacks16 hours ago

    Axsome Initiates Phase III Study on Depression Candidate

    Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.

  • What to Expect from Johnson & Johnson and Gilead Sciences’ EPS
    Market Realist21 hours ago

    What to Expect from Johnson & Johnson and Gilead Sciences’ EPS

    In its first-quarter earnings press release, Johnson & Johnson (JNJ) has increased its fiscal 2019 adjusted diluted operational EPS guidance from the previously projected $8.65 to $8.80, which implies YoY growth of 5.7%–7.6%, to $8.73–$8.83, which implies a YoY rise of 6.7%–7.9%. The company also increased the lower end and narrowed its fiscal 2019 adjusted diluted EPS guidance from $8.50–$8.65.

  • How Are Johnson & Johnson’s Revenues Trending in 2019?
    Market Realist23 hours ago

    How Are Johnson & Johnson’s Revenues Trending in 2019?

    In its first-quarter earnings conference call, Johnson & Johnson (JNJ) forecasted a stronger operational revenue growth outlook and expects YoY adjusted operational sales growth of 2.5% to 3.5% and operational sales growth of 0.5% to 1.5% for fiscal 2019. The company has also guided for a YoY reported sales decline of 1.5% to 0.5% for fiscal 2019 based on the euro spot rate of $1.12.

  • What Are Analysts Recommending for Johnson & Johnson and Gilead?
    Market Realistyesterday

    What Are Analysts Recommending for Johnson & Johnson and Gilead?

    Johnson & Johnson (JNJ) is up by 10.10%, and Gilead Sciences (GILD) is up by 10.92% on a YTD basis. Both the companies are struggling due to intense competitive pressures either from branded or generic competitors. The consensus recommendation for both Johnson & Johnson and Gilead Sciences is a “buy.”

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool2 days ago

    3 Top Healthcare Stocks to Buy Right Now

    These three healthcare stocks could be outstanding additions to your portfolio.

  • 3 Excellent Dividend Aristocrats You Can Buy Right Now
    Motley Fool2 days ago

    3 Excellent Dividend Aristocrats You Can Buy Right Now

    These quality businesses have lots of opportunities to keep raising what they give back to investors.

  • Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
    Zacks5 days ago

    Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma

    The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.

  • Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
    Zacks5 days ago

    Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

  • Bloomberg7 days ago

    Billions at Stake in Opioid Suits, But It's No Tobacco Windfall

    (Bloomberg) -- An Oklahoma case, the first of more than 1,600 lawsuits filed by U.S. state and local governments against opioid makers to go to trial, could serve as a key benchmark for governments hoping to recoup costs associated with the public health crisis.However, verdicts and legal settlements resulting from the litigation are likely to be smaller than the 1998 global settlement with tobacco companies and won’t significantly affect government budgets, according to Fitch Ratings.The tobacco settlement with 46 states compensated them with more than $200 billion for decades of tobacco-related health-care costs, but wasn’t enough to alter state and local government credit quality, according to Fitch. The opioid epidemic has taken place over a shorter time span, and hasn’t resulted in as many deaths, according to Marcy Block, a Fitch analyst.“It’s severe, but it’s less if you think about the amount of deaths through tobacco usage,” Block said.Ten TimesMore than 47,000 Americans died from opioid overdoses in 2017, including heroin and fentanyl, a synthetic opioid, according to the National Institute on Drug Abuse. Cigarette smoking is responsible for ten times as many deaths annually, according to the Centers for Disease Control and Prevention.Oklahoma sued Johnson & Johnson, Purdue Pharma LP and Teva Pharmaceutical Industries Ltd. in 2017, alleging the companies deceived the public by overstating the benefits of their drugs while downplaying the risk of addiction. Teva in May agreed to pay $85 million to resolve the suit. Purdue Pharma, the maker of OxyContin, agreed in March to pay $270 million.Read more about how opioid makers are getting squeezed as cities try to form a negotiating groupThe opioid litigation could cost the pharmaceutical industry between $5 billion and $50 billion, based on the 1998 tobacco deal and costs of the abuse epidemic, according to Bloomberg Intelligence analyst Holly Froum. Oklahoma is seeking at least $10 billion in damages and penalties for current and future outlays from Johnson & Johnson.“The depth of evidence against the opioid manufacturers, including any potential evidence of fraudulent marketing, will be a key determinant not only of how this case is decided, but the thousands of additional cases against the industry, “ wrote Rachel Barkley, a senior vice president at Loop Capital Markets earlier this month.“Additionally, the size of any settlement would likely serve as a benchmark in future cases,” she said.Securtitized ProceedsStates and local governments issued tens of billions of dollars in muni bonds backed by the tobacco settlement and some used that money to plug budget gaps. The securities are repaid with the money they receive each year from cigarette companies under the settlement. The amount of the payments is based on annual cigarette shipments. There are currently $85 billion of tobacco bonds outstanding, including debt issued to refinance previously issued securities.At least 42 states and more than 1,900 municipalities have sued opioid manufactures and distributors, blaming them for creating a national public-health crisis and demanding billions of dollars in damages.A U.S. federal judge in Cleveland is overseeing opioid litigation brought by U.S. cities and counties and has set two trials for October. The scope of the litigation could result in a global settlement that mimics the resolution to the tobacco cases in the 1990s.The CDC estimates that the total “economic burden” of prescription opioid misuse alone in the U.S. is $78.5 billion a year, including the costs of health care, lost productivity, addiction treatment and criminal justice involvement.Factoring the economic value of lives lost, the White House’s Council of Economic Advisers estimated the costs of the epidemic in 2015 totaled $504 billion.Related: States Are Suing Opioid Makers But Their Pensions Embrace ThemTo contact the reporter on this story: Martin Z. Braun in New York at mbraun6@bloomberg.netTo contact the editors responsible for this story: James Crombie at jcrombie8@bloomberg.net, Michael B. Marois, Shannon D. HarringtonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Big Drugmakers That May Tread the M&A Path After Pfizer
    Zacks7 days ago

    Big Drugmakers That May Tread the M&A Path After Pfizer

    There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

  • Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
    Zacks9 days ago

    Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $139.44, moving -0.46% from the previous trading session.

  • J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
    Zacks9 days ago

    J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

    J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

  • Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion
    Zacks12 days ago

    Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion

    Dassault's acquisition of Medidata (MDSO) to close by 2019-end.

  • Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
    Zacks12 days ago

    Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

    Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

  • Barrons.com13 days ago

    Johnson & Johnson Made the Right Call in Fighting Oklahoma Over Opioids, Analyst Says

    Teva Pharmaceutical and Purdue Pharma both settled with Oklahoma over allegations they contributed to the state’s opioid crisis.

  • Market Exclusive13 days ago

    Market Morning: Huawei Strikes Back, ‘No’ on No No Deal, Ancient Chinese Stoners, Crowded CrowdStrike

    Huawei Strikes Back…Against Verizon Chinese Telecom Huawei, pretty upset about President Trump’s sanctions against the company that have led to Alphabet (NASDAQ:GOOGL) banning the company from using its Android operating system for its phones among other things, is striking back by insisting that Verizon (NYSE:VZ) pay it $1 billion in licensing fees for 230 patents […]The post Market Morning: Huawei Strikes Back, 'No' on No No Deal, Ancient Chinese Stoners, Crowded CrowdStrike appeared first on Market Exclusive.

  • Barrons.com13 days ago

    Johnson & Johnson and Cisco Directors Are Buying Up Stock

    Lockheed CEO Marillyn Hewson made the first insider purchase of J&J stock this year, while Northrop Grumman Chairman Wes Bush bought up Cisco stock.

  • J&J, Colgate ordered to pay nearly $10 million in California talc cancer case
    CNBC14 days ago

    J&J, Colgate ordered to pay nearly $10 million in California talc cancer case

    Plaintiff Patricia Schmitz will be awarded $4.8 million in damages from each company.

  • How Analysts Rate Tandem Diabetes Care and Insulet
    Market Realist16 days ago

    How Analysts Rate Tandem Diabetes Care and Insulet

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?Evolving insulin delivery landscapeUntil the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson

  • Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May
    Motley Fool16 days ago

    Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May

    The biopharma company started several new clinical trials and enjoyed success in others since the start of the calendar year.

  • Why Investors Should Keep an Eye on the Oklahoma Opioid Trial Against Johnson & Johnson
    Motley Fool19 days ago

    Why Investors Should Keep an Eye on the Oklahoma Opioid Trial Against Johnson & Johnson

    The case, which is premised on a unproven legal theory, could impact the course of future opioid litigation.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper
    Zacks19 days ago

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper